- Home
- ARAY
ARAY
Accuray Incorporated
as 07-26-2024 4:00pm EST
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 178.6M | IPO Year: | 2007 |
| Target Price: | $8.25 | AVG Volume (30 days): | 530.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.46 - $4.30 | Next Earning Date: | 08-07-2024 |
| Revenue: | $430,554,000 | Revenue Growth: | -2.00% |
| Revenue Growth (this year): | -1.16% | Revenue Growth (next year): | 5.22% |
Stock Insider Trading Activity of Accuray Incorporated (ARAY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pervaiz Ali | ARAY | SVP Chief Financial Officer | Jun 4 '24 | Sell | $1.70 | 2,701 | $4,597.10 | 402,542 | SEC Form 4 |
| Chalke Sandeep | ARAY | SVP, Chief Commercial Officer | Jun 4 '24 | Sell | $1.70 | 26,799 | $45,611.90 | 531,341 | SEC Form 4 |
| WHITTERS JOSEPH E | ARAY | Director | May 28 '24 | Buy | $1.54 | 50,000 | $77,045.00 | 511,053 | SEC Form 4 |
| WHITTERS JOSEPH E | ARAY | Director | May 28 '24 | Buy | $1.58 | 50,000 | $79,000.00 | 561,053 | SEC Form 4 |
| Hoge Michael | ARAY | Senior VP Global Operations | Mar 1 '24 | Sell | $2.59 | 11,991 | $31,056.69 | 390,208 | SEC Form 4 |
| Pervaiz Ali | ARAY | SVP Chief Financial Officer | Jan 3 '24 | Sell | $2.74 | 2,116 | $5,800.17 | 402,743 | SEC Form 4 |
| Corradetti GIna | ARAY | VP, CAO and Controller | Jan 3 '24 | Sell | $2.74 | 14,129 | $38,729.00 | 196,138 | SEC Form 4 |
| Winter Suzanne C | ARAY | President | Nov 30 '23 | Sell | $2.47 | 65,390 | $161,624.46 | 1,369,811 | SEC Form 4 |
| Spine Patrick | ARAY | SVP, Chief Admin Officer | Nov 30 '23 | Sell | $2.47 | 14,832 | $36,652.84 | 219,484 | SEC Form 4 |
| Pervaiz Ali | ARAY | SVP Chief Financial Officer | Nov 30 '23 | Sell | $2.47 | 13,463 | $33,271.11 | 404,859 | SEC Form 4 |
| Chew Jesse | ARAY | SVP, General Counsel | Nov 30 '23 | Sell | $2.47 | 29,770 | $73,564.65 | 381,920 | SEC Form 4 |
| Chalke Sandeep | ARAY | SVP, Chief Commercial Officer | Nov 30 '23 | Sell | $2.47 | 14,585 | $36,040.99 | 555,640 | SEC Form 4 |
| Hoge Michael | ARAY | Senior VP Global Operations | Nov 30 '23 | Sell | $2.47 | 19,212 | $47,482.46 | 402,199 | SEC Form 4 |
| Pervaiz Ali | ARAY | SVP Chief Financial Officer | Oct 31 '23 | Sell | $2.58 | 3,303 | $8,533.96 | 401,857 | SEC Form 4 |
Latest Accuray Incorporated News
ARAY Breaking Stock News: Dive into ARAY Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Loss-Making Accuray Incorporated (NASDAQ:ARAY) Expected To Breakeven In The Medium-Term
Hospital Management
a month ago
Heidelberg University Hospital upgrades to Accuray’s Radixact System
PR Newswire
a month ago
Heidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care
Zacks
a month ago
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
MT Newswires
a month ago
Accuray, TrueNorth Medical Physics Collaborate on Radiation Oncology Support
PR Newswire
a month ago
Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients
Zacks
a month ago
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
Medical Device Network
a month ago
Accuray’s Precision treatment planning system gains approval in China
Compare ARAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARAY Accuray Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.